Teva launched its generic version of Uceris (budesonide) extended-release tablets in the U.S.

The drug, manufactured by Salix Pharmaceuticals, is a glucocorticosteroid indicated for remission in patients with active mild-to-moderate ulcerative colitis.

 “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, head of Teva North America Commercial.

Uceris had annual sales of approximately $196 million in the U.S. as of May 2018.